Bullish case
$360 to $450
More likely if BRUKINSA maintains global growth, margins hold, major pipeline or regulatory milestones are favorable, and investors keep assigning a premium multiple to the oncology platform.
BeOne Medicines AG research snapshot
ONC AI Stock Analysis
ONC AI stock analysis currently reads BeOne Medicines AG as a global oncology company whose commercial engine is led by BRUKINSA while its pipeline creates both optionality and event risk. The page uses scenario analysis, not a certain price prediction. At the July 8, 2026 cutoff, ONC closed at $301.88 and implied a market capitalization of about $33.56 billion. Q1 2026 revenue was $1.513 billion and GAAP net income was $227 million. This is informational research and not investment advice.
Current price
$301.88
Market cap
$33.56 billion
AI score
72 / 100
Rating
Profitable oncology growth, clinical and valuation risk
Trend status
Volatile consolidation, live confirmation required
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. BeOne has SEC filings, quarterly disclosures, commercial product data, clinical milestones, and active market coverage.
- bias Check
- The main AI bias risk is extrapolating recent BRUKINSA growth and pipeline potential too far. The analysis separates reported Q1 2026 facts from uncertain clinical, regulatory, competitive, and valuation outcomes.
- ai Confidence
- High data confidence
- investment Certainty
- Medium. Reported financial data are detailed, but drug development outcomes, pricing, competition, and market multiples can change the investment case quickly.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BeOne commercializes oncology medicines globally, led by BRUKINSA, and funds a broad hematology and solid-tumor pipeline. | High |
| Moat | The moat rests on clinical evidence, regulatory approvals, manufacturing scale, commercial reach, and accumulated development capability rather than a permanent monopoly. | Medium-high |
| Management | Founder-led management has scaled global commercialization and R&D, but must preserve capital discipline as the pipeline expands. | Medium |
| Financial trend | Q1 2026 revenue rose 35% year over year to $1.513 billion, while GAAP net income reached $227 million and operating cash flow was positive. | High |
| Valuation | The share price reflects continued commercial execution and pipeline progress. The safety margin narrows if growth, margins, or clinical milestones disappoint. | Medium-low |
| Technical trend | Volatile consolidation. Static levels offer a planning frame, but moving averages, momentum, and volume need live chart confirmation. | Medium |
| Risk level | Clinical, regulatory, pricing, competition, China exposure, pipeline spending, and valuation compression are material risks. | High |
| AI confidence | High for reported financial data and business mapping, but lower for drug approvals, trial readouts, and future market returns. | High data confidence |
| Investment certainty | Medium certainty because a strong reported quarter does not remove the binary risks embedded in oncology development and valuation. | Medium |
ONC AI stock forecast
ONC AI Stock Forecast Scenarios
The ONC AI stock forecast uses ranges around the $301.88 July 8, 2026 closing price rather than a point target. The reported Q1 result, BRUKINSA growth, pipeline execution, regulatory events, and the valuation multiple can all move the outcome.
Base case
$270 to $360
More likely if commercial execution remains solid but R&D spending, competition, and trial timing keep valuation expectations balanced.
Bearish case
$200 to $270
More likely if product growth slows, a trial or regulatory event disappoints, pricing pressure rises, or the market applies a lower multiple to biotechnology earnings.
ONC AI technical analysis
ONC AI Technical Analysis
ONC AI technical analysis starts from the $301.88 July 8, 2026 closing price. A June 8 chart snapshot showed a $239.25 to $385.22 52-week range and 50-day and 200-day averages of $301.26 and $320.34. Those indicators are dated, so confirm them with live chart data before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $301.88 | Closing price used for this page as of the July 8, 2026 data cutoff. |
| Near support | $270 to $280 | Planning zone based on the June chart snapshot and recent price range. It is not a guaranteed floor. |
| Near resistance | $320 to $340 | A sustained move above this area would improve the short-term setup, subject to live volume confirmation. |
| 50-day moving average | $301.26 on June 8, 2026 | Historical chart snapshot only. Confirm the current average before trading. |
| 200-day moving average | $320.34 on June 8, 2026 | Historical chart snapshot only. A live chart is required for current long-term trend confirmation. |
| Momentum | Mixed, confirmation required | Price near the dated 50-day average and below the dated 200-day average calls for current-chart confirmation. |
| Volume | 284,834 shares on June 8, 2026 | Use current volume relative to its average to judge breakout quality. |
| Volatility | High monitoring priority | Oncology news and clinical milestones can cause gaps that ordinary stop orders may not control. |
| Invalidation | Sustained close below $270 | A confirmed break below the support zone would weaken this short-term technical framework. |
ONC AI trading strategy
ONC AI Trading Strategy Framework
The ONC AI trading strategy is a rules-based research framework, not personalized advice. Pair any setup with position sizing, event-risk awareness, and current filing and chart checks.
Trend-following setup
Wait for ONC to hold above support and clear the resistance zone with live volume and moving averages that confirm improving momentum.
A failed breakout or sustained close below the defined support zone invalidates the setup.
Mean-reversion setup
If ONC approaches support without a business or clinical thesis break, compare the move with the latest BRUKINSA sales, cash position, guidance, and upcoming trial calendar.
Do not average down through a negative regulatory, safety, or trial-data change without reassessing the thesis.
Event-risk monitor
Track quarterly product revenue, gross margin, R&D, regulatory decisions, trial data, competitor readouts, and pricing developments.
Reduce exposure assumptions before binary events when a gap through a stop would exceed the planned loss.
Investment research summary
Four-master Research Compression
Business essence
BeOne sells oncology medicines worldwide and reinvests commercial cash generation into hematology and solid-tumor development.
Moat
Clinical data, approved medicines, regulatory infrastructure, manufacturing, and a global commercial organization make replication difficult, but patent and clinical advantages can erode.
Munger risk inversion
The thesis can fail through weaker BRUKINSA growth, clinical setbacks, approval delays, safety signals, payer pressure, competitor launches, or escalating development costs.
Management
John V. Oyler co-founded and leads BeOne. The key test is whether the company converts a large pipeline into durable returns without losing cost discipline.
Industry trend
Oncology demand and targeted therapy innovation support long-run opportunity, while payer scrutiny, trial complexity, and fast-moving standards of care constrain predictability.
Valuation and margin of safety
At $301.88, the market capitalization was verified at about $33.56 billion. The valuation depends on continued product growth and pipeline value, leaving a limited margin for execution errors.
Source-backed data
ONC Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ONC closing price | $301.88 | Macrotrends price history | July 8, 2026 |
| Market capitalization and ADS shares | $33.56 billion, verified as $301.88 x 111.174 million ADS equivalents | SEC Q1 2026 cover page and financial_rigor.py | July 8, 2026 |
| Q1 2026 revenue | $1.513 billion, up 35% year over year | BeOne Q1 2026 results, cross-checked with StockAnalysis | July 8, 2026 |
| Q1 2026 GAAP net income | $227.357 million | BeOne Q1 2026 results, cross-checked with MarketBeat | July 8, 2026 |
| Cash, cash equivalents and restricted cash | $4.853 billion at March 31, 2026 | BeOne Q1 2026 results, cross-checked with MarketBeat | July 8, 2026 |
| FY 2026 revenue guidance | $6.3 billion to $6.5 billion | BeOne Q1 2026 results | July 8, 2026 |
Frequently Asked Questions
Use Pineify AI Stock PickerBuild an AI trading strategyRun an AI stock screenerRead the ABBV AI stock analysis
This ONC AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of July 8, 2026, may be incomplete, and can be wrong if clinical results, filings, market prices, company events, or macro conditions change.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it